TY - JOUR
T1 - Nanotechnology-based strategies against SARS-CoV-2 variants
AU - Huang, Xiangang
AU - Kon, Edo
AU - Han, Xuexiang
AU - Zhang, Xingcai
AU - Kong, Na
AU - Mitchell, Michael J.
AU - Peer, Dan
AU - Tao, Wei
N1 - Funding Information:
The authors are supported by a US METAvivor Early Career Investigator Award (No. 2018A020560, W.T.), a Department Basic Scientist Grant (No. 2420 BPA075, W.T.), a Khoury Innovation Award (No. 2020A003219, W.T.), a Gillian Reny Stepping Strong Center for Trauma Innovation Breakthrough Innovator Award (No. 113548, W.T.), the Nanotechnology Foundation (No. 2022A002721, W.T.), the Farokhzad Family Distinguished Chair Foundation (No. 018129, W.T.), an AHA Collaborative Sciences Award (No. 2018A004190, W.T.), the Innovation Authority in Israel (Kamin-Corona; D.P.), a US National Institutes of Health (NIH) Director’s New Innovator Award (DP2 TR002776, M.J.M.), a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI; M.J.M.), the National Institutes of Health (NCI R01 CA241661, NCI R37 CA244911 and NIDDK R01 DK123049, M.J.M.), a US National Science Foundation CAREER Award (CBET-2145491, M.J.M.) and the Yoran Institute for Human Genome Research (E.K.).
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/10
Y1 - 2022/10
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.
KW - COVID-19/prevention & control
KW - Humans
KW - Nanotechnology
KW - Pandemics/prevention & control
KW - SARS-CoV-2/genetics
UR - http://www.scopus.com/inward/record.url?scp=85136491530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136491530&partnerID=8YFLogxK
U2 - 10.1038/s41565-022-01174-5
DO - 10.1038/s41565-022-01174-5
M3 - Review article
C2 - 35982317
AN - SCOPUS:85136491530
SN - 1748-3387
VL - 17
SP - 1027
EP - 1037
JO - Nature Nanotechnology
JF - Nature Nanotechnology
IS - 10
ER -